Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 18/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 18/20 | 0.68 |
| ▸ | PDE4A | P27815 | 3/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.60 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Revizinone SCHEMBL29557974 | 1.00 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Revizinone SCHEMBL9584593 | 1.00 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Revizinone SCHEMBL7297062 | 1.00 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9584441 | 0.91 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9584347 | 0.91 | PDE3B (0.72) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9584335 | 0.91 | PDE3B (0.72) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9583358 | 0.91 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9583372 | 0.91 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Water SCHEMBL9583851 | 0.90 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Water SCHEMBL9583863 | 0.90 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0406958-B1 | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-03-15 | — | — | EP | claimed |
| US-5043327-A | Treating mammals with congestive heart failure | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-27 | — | — | US | claimed |
| US-12122786-B2 | Inhibitors of cyclic mono- and di-nucleotide phosphodiesterases and the uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220194957-A1 | INHIBITORS OF CYCLIC MONO- AND DI-NUCLEOTIDE PHOSPHODIESTERASES AND THE USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2022-06-23 | — | — | US | disclosed |
| US-5220023-A | Intermediates for inotropic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-06-15 | — | — | US | disclosed |
| US-5043327-A | Treating mammals with congestive heart failure | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194957-A1 | INHIBITORS OF CYCLIC MONO- AND DI-NUCLEOTIDE PHOSPHODIESTERASES AND THE USES THEREOF | CGAS, DTYMK, PDE7A | PDE3B 35/4885PDE3A 32/4885PDE4A 7/4885 |
| US-12122786-B2 | Inhibitors of cyclic mono- and di-nucleotide phosphodiesterases and the uses thereof | DTYMK, CGAS, PDE7A | PDE3B 18/4885PDE3A 16/4885PDE4A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.